These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34593621)

  • 41. Are prophylactic antibiotics necessary prior to transarterial chemoembolization for hepatocellular carcinoma in patients with native biliary anatomy?
    Watchmaker JM; Lipnik AJ; Fritsche MR; Baker JC; Mouli SK; Geevarghese S; Banovac F; Omary RA; Brown DB
    J Surg Oncol; 2018 May; 117(6):1312-1317. PubMed ID: 29513895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma.
    Furuta M; Moriguchi M; Okuda K; Kataoka S; Mizuno N; Takemura M; Taketani H; Hara T; Seko Y; Umemura A; Nishikawa T; Yamaguchi K; Yasui K; Minami M; Itoh Y
    Dig Dis; 2018; 36(5):385-394. PubMed ID: 29969764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Wang Z; Zhang H; Zhao H; Wang X; Tsauo J; Luo X; Li X
    Diagn Interv Radiol; 2014 Nov; 20(6):487-91. PubMed ID: 25297389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of transcatheter arterial chemoembolization and anti-PD-L1 liposomes therapy suppressed hepatocellular carcinoma progression in mice.
    Li J; Zhang L; Tao Y; Sun Z; Ge Y; Hu S
    Eur J Pharm Sci; 2023 Oct; 189():106549. PubMed ID: 37524271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of transcatheter arterial chemoembolization combined with 125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma.
    Zhang H; Yang A; Zhang J
    J BUON; 2020; 25(2):952-958. PubMed ID: 32521891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
    Marinelli B; Kim E; D'Alessio A; Cedillo M; Sinha I; Debnath N; Kudo M; Nishida N; Saeed A; Hildebrand H; Kaseb AO; Abugabal YI; Pillai A; Huang YH; Khan U; Muzaffar M; Naqash AR; Patel R; Fischman A; Bishay V; Bettinger D; Sung M; Ang C; Schwartz M; Pinato DJ; Marron T
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer.
    Jin J; Zhou T; Lou J; Yan S; Wu Y; Xie M; Wang W
    J BUON; 2020; 25(6):2584-2591. PubMed ID: 33455100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
    Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
    Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Establishment of a predictive model for short-term efficacy of transcatheter arterial chemoembolization treatment in hepatocellular carcinoma and its clinical application.
    Wei J; Wang Z
    J Cancer Res Ther; 2019; 15(4):941-946. PubMed ID: 31436256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of transcatheter arterial chemoembolization combined with thymosin alpha 1 on the autophagy of immune cells from advanced hepatocellular carcinoma].
    Fang SJ; Zheng LY; Zhao ZW; Fan XX; Xu M; Ji JS
    Zhonghua Yi Xue Za Zhi; 2017 Jul; 97(25):1942-1946. PubMed ID: 28693071
    [No Abstract]   [Full Text] [Related]  

  • 57. Sorafenib combined with transarterial chemoembolization prolongs survival of patients with advanced hepatocellular carcinoma.
    Liu Q; Dai Y
    J BUON; 2020; 25(2):945-951. PubMed ID: 32521890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
    Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.